Oramed Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Oramed Pharmaceuticals Inc (ORMP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.7% of the shares are freely tradable; institutional investors hold 37.1%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Mercer Global Advisors Inc. | 9.16 | 3,810,540 | +99.4 | 06/30/2026 |
| Aquamarine Financial (Cayman) Ltd | 6.04 | 2,512,175 | +18.9 | 06/30/2026 |
| Gem Investment Advisors, LLC | 4.81 | 1,998,802 | +21.9 | 06/30/2026 |
| BlackRock Inc | 3.87 | 1,608,111 | +1,644.3 | 06/30/2026 |
| Murchinson Ltd. | 3.10 | 1,290,294 | -1.9 | 06/30/2026 |
| BML Capital Management LLC | 2.08 | 866,269 | -72.6 | 06/30/2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.39 | 578,638 | -3.7 | 06/30/2026 |
| Geode Capital Management, LLC | 1.20 | 500,690 | +1,962.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 2.03 | 844,615 | -1.1 | 09/30/2026 |
| Fidelity Small Cap Index | 0.91 | 378,478 | +0.5 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Kidron Nadav | President and CEO | 4,140,505 | 16,976,071 $ | Sep 24, 2026 | direct |
| Kidron Miriam | Chief Scientific Officer | 1,550,554 | 6,357,271 $ | Sep 24, 2026 | direct |
| Hexter Joshua | COO & CBO | 1,328,130 | 5,445,333 $ | Oct 1, 2026 | direct |
| Gabay Avraham | Chief Financial Officer | 861,076 | 3,530,412 $ | Oct 1, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Gabay Avraham | Chief Financial Officer | Sell | 20,000 | 4.51 | 90,200 |
| Oct 1, 2026 | Hexter Joshua | COO & CBO | Sell | 30,000 | 4.51 | 135,330 |
| Sep 24, 2026 | Kidron Nadav | President and CEO | Other | 368,765 | – | – |
| Sep 24, 2026 | Kidron Nadav | President and CEO | Other | 349,497 | – | – |
| Sep 24, 2026 | Hexter Joshua | COO & CBO | Other | 209,291 | – | – |
| Sep 24, 2026 | Hexter Joshua | COO & CBO | Other | 75,455 | – | – |
| Sep 24, 2026 | Kidron Miriam | Chief Scientific Officer | Other | 209,291 | – | – |
| Sep 24, 2026 | Kidron Miriam | Chief Scientific Officer | Other | 208,125 | – | – |
| Sep 24, 2026 | Gabay Avraham | Chief Financial Officer | Other | 209,291 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.